Welcome to our dedicated page for Zimmer Biomet news (Ticker: ZBH), a resource for investors and traders seeking the latest updates and insights on Zimmer Biomet stock.
Zimmer Biomet Holdings, Inc. reports developments across its global medical technology business, including orthopedic reconstructive implants, surgical products, and integrated digital and robotic technologies that use data, analytics and artificial intelligence. Company updates commonly cover quarterly results and guidance, dividend actions, health care conference appearances, executive leadership changes, and clinical or operational data presented at orthopedic meetings.
Product-focused announcements describe musculoskeletal care technologies such as Oxford Cementless Partial Knee, Persona OsseoTi Keel Tibia, and HAMMR Automated Hip Impaction System, alongside broader portfolio themes in knees, hips, smart implants, robotics, AI and medical education.
Zimmer Biomet (NYSE: ZBH) will present new clinical and operational data and showcase robotic, digital and implant innovations at the AAOS 2026 Annual Meeting on March 5-9, 2026. The company will feature products including ROSA Knee with OptimiZe, Persona IQ, Monogram TKA, Oxford Cementless Partial Knee and Z1 Femoral Hip.
Arnold Schwarzenegger will appear as the conference Presidential Guest Speaker on March 5 at 10:30 a.m. CT alongside CEO Ivan Tornos and AAOS President Ned Amendola; multiple poster and data presentations will address safety, gait metrics, readmissions and ASC efficiency.
Zimmer Biomet (NYSE: ZBH) announced a quarterly cash dividend of $0.24 per share for Q1 2026. The dividend is payable on or about April 30, 2026 to shareholders of record at the close of business on March 31, 2026.
Zimmer Biomet (NYSE: ZBH) reported Q4 2025 net sales of $2.244B (up 10.9% reported; 5.4% organic constant currency) and full-year sales of $8.232B (up 7.2% reported; 3.9% organic). GAAP diluted EPS were $0.70 Q4 and $3.55 FY; adjusted EPS were $2.42 Q4 and $8.20 FY. The company generated $1.697B operating cash flow and $1.172B free cash flow, closed three acquisitions, and announced a new $1.5B share repurchase authorization commencing Feb 9, 2026. Full-year 2026 guidance targets ~2.5%–4.5% reported revenue growth and adjusted EPS of $8.30–$8.45.
Zimmer Biomet (NYSE: ZBH) announced its fourth-quarter 2025 earnings conference call will be webcast on Tuesday, February 10, 2026 at 8:30 a.m. ET. A news release with quarterly results will be published the same day at 6:30 a.m. ET. A live audio webcast and replay will be available via the company's investor relations site: https://investor.zimmerbiomet.com. U.S. and Canada dial-in is (800) 330-6710; international callers may use +1 (213) 279-1505. Use conference ID 7090861 to join the call.
Zimmer Biomet (NYSE: ZBH) announced that members of its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 8:15 a.m. PT (11:15 a.m. ET).
A live webcast will be available on Zimmer Biomet's Investor Relations website and will be archived for replay after the conference.
Zimmer Biomet (NYSE: ZBH) announced a quarterly cash dividend of $0.24 per share for the fourth quarter of 2025. The dividend is payable on or about January 30, 2026 to stockholders of record at the close of business on December 30, 2025.
Zimmer Biomet (NYSE: ZBH) and OneStep announced an exclusive collaboration to integrate OneStep's clinically validated mobility intelligence into Zimmer Biomet's mymobility Care Management Platform for joint replacement patients, effective Dec 16, 2025.
The integration will feed smartphone-based gait and functional mobility analytics (iPhone and Android) directly into mymobility to support remote assessment, patient engagement, and clinician-tailored rehabilitation. OneStep processes more than one million gait cycles every day, providing a large real-world mobility dataset to quantify recovery trends and functional outcomes.
Zimmer Biomet (NYSE: ZBH) announced U.S. FDA 510(k) clearance of ROSA® Knee with OptimiZe™, an enhanced version of its ROSA Knee robotic system for total knee replacement surgery.
The update adds five OptimiZe features—Planning, Landmarking, Tracking, Kinematic Alignment and Experience—plus integration with ZBEdge® Analytics. The company said OptimiZe Planning™ can reduce planning time by an average of 46%. Zimmer Biomet plans a targeted release later in 2025 and expects U.S. commercial availability in Q1 2026.
Zimmer Biomet (NYSE: ZBH) said members of its management team will present at the Annual Jefferies Global Healthcare Conference in London on Tuesday, Nov. 18, 2025 at Noon GMT (7 a.m. ET). A live webcast will be available on the company's investor relations website and will be archived for replay after the conference.
Zimmer Biomet (NYSE: ZBH) reported third quarter 2025 results on November 5, 2025: net sales $2.001B, up 9.7% reported, 8.6% on a constant currency basis and 5.0% on an organic constant currency basis. Net earnings $230.9M and adjusted diluted EPS $1.90 (+9.2%). The company completed the acquisition of Monogram Technologies and closed the April Paragon 28 acquisition, expanding robotics and extremities portfolios. Japan PMDA approval was received for the iodine-treated iTaperloc Complete and iG7 Hip System. Full-year 2025 reported revenue and adjusted EPS guidance are maintained while constant-currency revenue ranges were narrowed.